Comparative Pharmacology
Head-to-head clinical analysis: CLARINEX D 24 HOUR versus TAVIST 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARINEX D 24 HOUR versus TAVIST 1.
CLARINEX D 24 HOUR vs TAVIST-1
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desloratadine is a long-acting tricyclic histamine antagonist with selective peripheral H1-receptor antagonist activity. Loratadine is a long-acting antihistamine that selectively antagonizes peripheral H1-receptors.
TAVIST-1 (clemastine fumarate) is a first-generation antihistamine that acts as a competitive antagonist at histamine H1 receptors, thereby preventing histamine-mediated effects such as vasodilation, increased capillary permeability, and bronchoconstriction. It also exhibits anticholinergic and sedative properties.
1 tablet (5 mg desloratadine/120 mg pseudoephedrine) orally once daily
1.34 mg orally twice daily; maximum 8.04 mg/day.
None Documented
None Documented
Desloratadine: terminal t1/2 27 hours (range 20-50h) supporting once-daily dosing. Pseudoephedrine: t1/2 5-8 hours (up to 16h in alkaline urine).
Terminal half-life 12–15 hours; clinical dosing interval every 12 hours.
Desloratadine: ~87% excreted as metabolites (41% urine, 43% feces), <2% unchanged. Pseudoephedrine: ~70-90% excreted unchanged in urine.
Primarily renal: ~60% unchanged; biliary/fecal: ~30% as metabolites; minor via feces.
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine